Longer Main-Artery Ablation Enters a Randomized Renal Denervation Test
Renal denervation is being pushed one step closer to procedural precision. A prospective, multicenter randomized trial in China is comparing whether extending radiofrequency ablation in the main renal arteries from 1 minute to 2 minutes produces a larger blood pressure reduction in patients with hypertension.
The study, titled The Effect of Ablation Duration of Renal Denervation on Antihypertensive Efficacy and registered as NCT07876479, is designed around a simple but clinically important question: how much ablation time is enough to interrupt renal sympathetic signaling without changing the rest of the procedure? Investigators plan to enroll 220 patients and assign them 1:1 to two treatment strategies, both built around the same multielectrode radiofrequency catheter and the same digital subtraction angiography guidance.
A single minute may not fully suppress the sympathetic fibers encircling the main renal arteries. A second minute could deepen the lesion set where the anatomy is most favorable for energy delivery, potentially translating into more durable sympathetic interruption and a larger fall in blood pressure.
Trial Design Centers on Duration, Not Device Replacement
The intervention is not a comparison of different platforms or operators. Every participant undergoes catheter-based renal denervation with a single-use multielectrode renal denervation catheter, and both groups receive the same procedure under DSA guidance. The only planned difference is ablation time in the main renal arteries.
In Group 1, each ablation site in the main renal arteries and their branches is treated for 1 minute. In Group 2, each ablation site in the main renal arteries is treated for 2 minutes, while branch ablation remains at 1 minute. By keeping the branch strategy constant, the protocol isolates the potential benefit of prolonged treatment in the larger proximal vessels, where anatomy may allow more consistent energy delivery and where sympathetic fibers may still be accessible to deeper lesions.
That design matters because renal denervation has long struggled with a basic procedural problem: how to standardize a biologically variable intervention. Nerve depth, vessel caliber, branch distribution, and catheter contact all influence the eventual denervation burden. A longer dwell time at the main renal artery could compensate for some of that variability, but it could also add procedural time without improving the physiologic effect. This trial is built to answer precisely that tension.
Blood Pressure Entry Criteria Select a High-Risk Hypertensive Cohort
Eligibility is tightly defined. Participants must be men or women aged 20 to 80 years with a history of hypertension lasting at least 3 months. Entry blood pressure thresholds require either clinic systolic pressure of at least 150 mmHg but less than 180 mmHg and/or clinic diastolic pressure of at least 90 mmHg, along with a 24-hour mean systolic pressure of at least 140 mmHg but less than 170 mmHg.
Baseline treatment status also matters. Eligible patients are receiving 1 to 3 standard antihypertensive medications, or they cannot tolerate those drugs because of contraindications or adverse drug reactions. The enrollment frame therefore captures a population in which hypertension remains inadequately controlled despite medication exposure, but it does not extend to the most complex or unstable cardiovascular cases.
Several exclusions narrow the cohort further. Pregnancy, significant renal artery anatomic abnormalities, eGFR below 40 mL/min/1.73 m², solitary kidney, prior kidney transplantation, secondary hypertension, contrast allergy, recent major surgery, recent acute coronary syndrome, orthostatic hypotension, severe bleeding risk, recent thromboembolic or cerebrovascular events, severe peripheral vascular disease, severe valvular disease, recent atrial arrhythmias, implanted pacing or defibrillation hardware, serious comorbid illness, and acute systemic infection all remove patients from consideration. The result is a relatively controlled interventional population chosen to minimize procedural and renal safety concerns.
Why the Main Renal Arteries Matter
Renal denervation aims to interrupt renal sympathetic nerves that contribute to blood pressure elevation through renal sodium handling, renin release, and broader autonomic activation. In that physiology, lesion depth and continuity are not cosmetic variables; they determine whether the intervention reaches enough neural tissue to matter. Main renal arteries may offer a more stable target than smaller branches, and longer ablation there may produce broader thermal penetration into the perivascular nerve plexus.
Still, the branches remain part of the protocol in both groups. Maintaining 1-minute ablation in the branch vessels preserves a consistent peripheral treatment component while the main arteries become the experimental variable. That structure should help determine whether the proximal segment deserves a different procedural standard than the distal anatomy.
Follow-up Will Track Blood Pressure at 1, 3, 6, and 12 Months
Participants are followed at 1, 3, 6, and 12 months after the procedure. Blood pressure and prespecified clinical outcomes will be assessed across those visits, giving the study a year-long window to observe whether any advantage from longer ablation appears early, persists, or fades.
The primary objective is straightforward: determine whether moving from 1 minute to 2 minutes of ablation at each main renal artery site yields greater blood pressure reduction. Secondary clinical interpretation will depend on whether any gain justifies a potentially longer procedure and whether the benefit can be reproduced across centers.
Procedural Standardization Is the Real Test
This study arrives at a point where renal denervation is no longer being asked simply whether it can lower blood pressure. It is being asked how to do it with enough consistency that procedural differences do not overwhelm patient-level biology. The trial’s randomized, double-masked design for participants and outcomes assessors, along with parallel assignment, increases the chance that any observed difference will be tied to ablation duration rather than expectation or measurement bias.
The estimated enrollment of 220 patients and the planned completion timeline through 2029 leave a long runway before any answer emerges. For now, the study stands as a protocol-level attempt to optimize a device-based hypertension therapy by adjusting one of its most basic technical variables: how long energy is delivered to the main renal arteries.